Important Safety Information
Indications for Use (IFU): The MRIdian Linac system, with magnetic resonance imaging capabilities, is intended to provide stereotactic radiosurgery and precision radiotherapy for lesions, tumors, and conditions anywhere in the body where radiation treatment is indicated. The MRIdian Linac System is not appropriate for all patients, including those who are not candidates for magnetic resonance imaging.
Important Safety Information (ISI): Radiation treatments may cause side effects that can vary depending on the part of the body being treated. The most frequent ones are typically temporary and may include, but are not limited to, irritation to the respiratory, digestive, urinary or reproductive systems; fatigue; nausea; skin irritation; and hair loss. In some patients, side effects can be severe. Treatment sessions may vary in complexity and duration.
Radiation treatment is not appropriate for all cancers. You should discuss the potential for side effects and their severity as well as the benefits of radiation and magnetic resonance imaging with your doctor to make sure radiation treatment is right for you.
Disclaimer: The opinions and clinical experiences presented herein are specific to the featured physicians and the featured patients and are for information purposes only. Nothing in this material is intended to provide specific medical advice or to take the place of written law or regulations. Results of treatment presented in the videos and information on this webpage are not indicative of typical or future results.
Discuss treatment options with your doctor, including the risks and benefits of the entire course of treatment specific to your individual needs. MRIdian Linac systems are only available at appropriately equipped facilities with specially trained physicians.
MRIdian Radiation Therapy for Pancreatic Cancer
Key Clinical Study
A retrospective study at five MRIdian centers showed that high-dose adaptive treatment improves overall survival and eliminates serious toxicity in patients with pancreatic cancer.
Ongoing Clinical Study
Stereotactic MRI-Guided On-Table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer
High-dose magnetic resonance imaging (MRI) guided hypofractionated radiation therapy delivered using daily adaptive dose planning has been shown in a retrospective study to result in improved overall survival, relative to patients receiving lower radiation doses, in patients with locally advanced pancreatic cancer, without increasing the rate of serious gastrointestinal toxicity.
The goal of the proposed trial is to investigative in a controlled, prospective manner the robustness of this outcome, and to track quality of life over a 5-year trial period.
Eligible Participants
Patients with borderline resectable or inoperable locally advanced pancreatic cancer who are 18 years and older and meet the inclusion and exclusion criteria noted within the study description.
Trial Design
In this single-arm study, participants will receive radiation therapy using integrated magnetic resonance imaging (ViewRay’s MRIdian MR-Guided Radiation Therapy System) at a dose of 50 Gray in 5 fractions (treatment sessions). Fractions will be delivered at least twice per week and with at least 18 hours between treatments. Each participant will be aligned in the treatment system with MRI-guidance. On-table adaptive replanning will be used when clinically indicated. In all patients, real-time MR-imaging will be used throughout treatment delivery to monitor the target location and control the radiation beam, as necessary.
Outcome Measures
The primary outcome measure of the study is grade 3 or higher gastrointestinal toxicity in the first 90 days after treatment. Secondary measures include overall survival at two years, distant progression-free survival at six months, and changes in patient-reported quality of life (pre-treatment to 12 months post-treatment and for longer periods up to five years).
Videos Related To Pancreatic Cancer
Patient Story: John Hadley, Pancreatic Cancer
Patient Story: John Hadley, Pancreatic Cancer
Pancreatic Cancer Patient John Hadley and his son-in-law Dave Vincent, former CEO of Gamma West, share John’s story of MRIdian treatment and how he beat the disease.
February 1, 2021
Patient Story: Tom Tassie, Pancreatic Cancer
Pancreatic Cancer Patient Tom Tassie shares his story of MRIdian treatment and how he beat the statistics shared with him by his first clinician.
September 22, 2020
Patient Story: Michael Vaquero, Pancreatic Cancer
August 13, 2020
ViewRay MRIdian for Prostate, Breast, and Pancreatic Cancer Treatment
October 22, 2019
MRI-Guided Radiation Therapy Panel
Radiation oncology experts from across the country gathered to discuss the potential of MRI-guided radiotherapy.
Miami Cancer Institute, Baptist Health South Florida
September 28, 2018
October 8, 2018
Recent Pancreatic Cancer Webinar
Pancreatic Cancer in 2020: Surgery and Radiotherapy at the Cutting Edge
Join us for a multi-disciplinary, multi-institutional webinar uniting some of the best and brightest minds in pancreatic cancer care from the U.S. and U.K. We’ll hear from experts committed to advancing care, offering new treatment options, extending life, and improving quality of life for patients and their families battling this deadly disease.
Scientific Presentations Related To Pancreatic Cancer
MRIdian Solutions for Pancreas Cancer; Dr. Michael Chuong, Miami Cancer Institute
MR-Guided SBRT for Pancreas with On-Table Adaptation on MRIdian – MCI Experience
Michael Chuong, MD
Miami Cancer Institute, Baptist Health South Florida
ASTRO 2019
Dr. Chuong has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.
SMART: Status Update on the First Prospective, Multi-Institutional Study on Ablative Pancreas SBRT
Parag Parikh, MD
Henry Ford Health System
ASTRO 2019
Dr. Parikh has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.
Quantitative Radiomics of Daily 0.35T MR Images for Prediction of Tumor Response in Pancreas and Liver
John Chetley Ford, PhD
Sylvester Comprehensive Cancer Center, University of Miami Health System
ASTRO 2018
Dr. Ford has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.
High Dose, On-Table, Adaptive Radiation Therapy for Pancreatic Cancer: Encouraging Early Results
Michael Bassetti, M.D., Ph.D. | Assistant Professor, Radiation Oncology
University of Wisconsin, Carbone Cancer Center
Miami Symposium (2018)
Dr. Bassetti has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.
Improving Pancreatic Cancer Survival by using MR Guided Adaptive Radiation
Parag Parikh, BSE, MD
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine – St. Louis, MO
ASTRO 2017
Dr. Parikh has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.
From Anatomical to Functional-based MR Guided Adaptive Radiotherapy: The UCLA Experience
Percy Lee, MD
UCLA Health, Jonsson Comprehensive Cancer Center – Los Angeles, CA
ASTRO 2017
Dr. Lee has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.
Clinical Experience with MR-guided Radiation Therapy for Pancreatic Tumors at VUmc
Anna Bruynzeel, MD, PhD
VUmc – Amsterdam, The Netherlands
ASTRO 2017
Dr. Bruynzeel has been compensated by ViewRay for her services in preparing and presenting this material for ViewRay’s further use and distribution.
Daily Adaptive Planning for Pancreatic Cancer
Frank Lagerwaard, MD
VUmc – Amsterdam, The Netherlands
ASTRO 2017
Dr. Lagerwaard has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.
Considerations and Challenges of MR Guided RT
John Bayouth, PhD
Carbone Cancer Center, University of Wisconsin – Madison, WI
ESTRO 37 (2018)
Dr. Bayouth has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.
About MRIdian
The MRIdian Linac system, with magnetic resonance imaging capabilities, is intended to provide stereotactic radiosurgery and precision radiotherapy for lesions, tumors, and conditions anywhere in the body where radiation treatment is indicated. The MRIdian Linac System is not appropriate for all patients, including those who are not candidates for magnetic resonance imaging.
Radiation treatments may cause side effects that can vary depending on the part of the body being treated. The most frequent ones are typically temporary and may include, but are not limited to, irritation to the respiratory, digestive, urinary or reproductive systems; fatigue; nausea; skin irritation; and hair loss. In some patients, side effects can be severe. Treatment sessions may vary in complexity and duration.
Radiation treatment is not appropriate for all cancers. You should discuss the potential for side effects and their severity as well as the benefits of radiation and magnetic resonance imaging with your doctor to make sure radiation treatment is right for you.
Results of treatment presented in the videos on this webpage are not indicative of typical or future results. Discuss treatment options with your doctor, including the risks and benefits of the entire course of treatment specific to your individual needs. MRIdian Linac systems are only available at appropriately equipped facilities with specially trained physicians.